The treatment of ventricular rhythm disturbances.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000097:blood / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D005117:Cardiac Complexes, Premature / Q000175:diagnosis; D004206:Disopyramide / Q000627:therapeutic use; D004554:Electric Countershock; D004558:Electric Stimulation; D004562:Electrocardiography / Q000379:methods; D005080:Exercise Test; D005424:Flecainide; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D008012:Lidocaine / Q000031:analogs & derivatives / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D012306:Risk; D013610:Tachycardia / Q000503:physiopathology / Q000628:therapy; D016677:Tocainide; D014481:United States; D014693:Ventricular Fibrillation / Q000628:therapy; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D010880:Piperidines; D016677:Tocainide; D010672:Phenytoin; D008012:Lidocaine; D014700:Verapamil; D004206:Disopyramide; D011802:Quinidine; D005424:Flecainide; D011342:Procainamide